证券代码：300723 证券简称：一品红 公告编号：2025-078 一品红药业集团股份有限公司 关于变更全资子公司签署《技术服务（委托）合同》内容 暨调整关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、2024 年 4 月 3 日，一品红药业集团股份有限公司（以下简称"公司"） 公司子公司广州瑞安博医药科技有限公司（以下简称"广州瑞安博"）与博济医药 科技股份有限公司（以下简称"博济医药"）签订了《技术服务（委托）合同》， 合同总金额为人民币 6,963 万元。上述事项具体情况见公司披露的《关于控股子 公司签订日常经营合同的自愿性披露公告》（公告编号：2024-009）。2024 年 9 月 29 日，公司召开第四届董事会第三次会议，补充确认博济医药为公司关联方， 公司与博济医药自 2024 年 7 月 19 日起发生的交易确认为关联交易。具体情况 见公司披露的《关于确认关联方及其关联交易的公告》（公告编号：2024-077）。 2、鉴于原合同执行过程中新增病例数及延伸治疗服务需求，双方补充签订 了《"化药 1 类新药 A ...

证券代码：300723 证券简称：一品红 公告编号：2025-073 一品红药业集团股份有限公司 2025 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无变更、否决议案的情况； 2、本次股东大会未涉及变更以往股东大会决议的情形； 3、本次股东大会采取现场投票与网络投票表决相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开的日期、时间： （1）现场会议时间：2025 年 11 月 18 日（星期二）下午 14：30 开始。 式召开。 （2）网络投票时间：2025 年 11 月 18 日。 ①通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 11 月 18 日交 易日上午 9：15—9：25，9：30-11：30，下午 13：00-15：00。 ②通过深圳证券交易所互联网系统投票的时间为 2025 年 11 月 18 日上午 9:15 至下午 15:00。 2、现场会议召开地点：广州市黄埔区广州国际生物岛寰宇一路 27 号云润大厦 22 层会议室。 4、股东大会召集 ...

北京市中伦（广州）律师事务所 关于一品红药业集团股份有限公司 2025 年第三次临时股东大会的 法律意见书 致：一品红药业集团股份有限公司 北京市中伦（广州）律师事务所（以下简称"本所"）受一品红药业集团股份有 限公司（以下简称"公司"）委托，指派本所律师邵芳、谢兵（以下简称"本所律师"） 出席公司 2025 年第三次临时股东大会（以下简称"本次股东大会"）。本所律师根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司股东会规则》 等有关法律、法规、规范性文件及《一品红药业集团股份有限公司章程》（以下 简称"《公司章程》"）的规定，对公司本次股东大会进行见证并出具法律意见。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为作为出具本法律意见书 所必需的材料，所提供的原始材料、副本、复印件等材料、口头证言均符合真实、 准确、完整的要求，有关副本、复印件等材料与原始材料一致。 在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、出席本 次股东大会人员和召集人的资格、会议表决程序及表决结果是否符合《公司法》 《上市公司股 ...

具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）上披露 的《关于 2024 年员工持股计划第一个解锁期解锁条件成就的公告》（公告编号： 2025-077）。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 一品红药业集团股份有限公司（以下简称"公司"）第四届监事会第十二次 会议于 2025 年 11 月 18 日上午 11：30 以现场结合通讯表决方式召开。本次会议 通知已于 2025 年 11 月 14 日以电话或电子邮件等方式向全体监事发出。会议由 监事会主席黄良雯女士主持，会议应到监事 3 人，实到监事 3 人，公司高管列席 会议。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律 法规以及《一品红药业集团股份有限公司章程》的有关规定。 二、监事会会议审议情况 1、审议通过《关于 2024 年员工持股计划第一个解锁期解锁条件成就的议 案》 监事会认为：公司本次员工持股计划第一个锁定期设定的公司层面 2024 年 业绩考核目标及持有人个人层面绩效考核目标均已达成，解锁条件已成就，解锁 ...

一、董事会会议召开情况 一品红药业集团股份有限公司（以下简称"公司"）第四届董事会第十三次 会议于 2025 年 11 月 18 日 11：00 以现场结合通讯表决方式召开。经全体董事 同意豁免会议通知时间要求，于当日以口头方式通知了全体董事。会议由董事长 李捍雄先生主持，会议应到董事 5 人，实到董事 5 人。公司监事、高管列席会议。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法规以 及《一品红药业集团股份有限公司章程》的有关规定。 二、董事会会议审议情况 1、审议通过《关于 2024 年员工持股计划第一个解锁期解锁条件成就的议 案》 公司 2024 年员工持股计划（以下简称"本次员工持股计划"）第一个锁定期 于 2025 年 10 月 11 日届满，根据公司《一品红药业集团股份有限公司 2024 年 员工持股计划（草案）》规定，第一个解锁期解锁条件已成就，本次解锁比例为 本次员工持股计划持股总数的 30%，可解锁的标的股票数量为 1,534,831 股，占 公司目前总股本的 0.34%。本次员工持股计划第一个锁定期解锁之后，管理委员 会将根据持有人会议的授权处置员工持股计划的权益。本 ...

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 187.22%, but recent trends indicate a decline over the past 20 and 60 days [1][2]. Financial Performance - For the period from January to September 2025, Yipinhong reported revenue of 814 million yuan, a year-on-year decrease of 34.35%, while the net profit attributable to shareholders was -136 million yuan, an increase of 44.80% compared to the previous year [2]. - The company has distributed a total of 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the last three years [3]. Stock Market Activity - As of November 18, Yipinhong's stock price was 49.00 yuan per share, with a market capitalization of 22.133 billion yuan. The stock experienced a 2.02% decline during the trading session [1]. - The stock has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) five times this year, with the most recent appearance on July 21, where it recorded a net buy of 65.576 million yuan [1]. Shareholder Information - As of October 31, Yipinhong had 20,700 shareholders, an increase of 9.42% from the previous period, with an average of 20,156 shares held per shareholder, a decrease of 8.61% [2]. - New institutional shareholders include Hong Kong Central Clearing Limited and several mutual funds, while E Fund Healthcare Industry Mixed A has exited the top ten shareholders list [3]. Business Overview - Yipinhong, established on February 4, 2002, and listed on November 16, 2017, is primarily engaged in the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals. The revenue composition includes 61.12% from pediatric drugs, 22.71% from chronic disease drugs, and 16.17% from other products [1].

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 207.74%, but recent trends indicate a decline over the past 60 days [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002. It was listed on November 16, 2017. The company focuses on the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The main revenue composition includes children's medicine (61.12%), chronic disease medicine (22.71%), and others (16.17%) [1]. Financial Performance - For the period from January to September 2025, Yipinhong reported an operating income of 814 million yuan, a year-on-year decrease of 34.35%. The net profit attributable to the parent company was -136 million yuan, an increase of 44.80% year-on-year [2]. - Since its A-share listing, Yipinhong has distributed a total of 335 million yuan in dividends, with 151 million yuan distributed over the past three years [3]. Shareholder Information - As of October 31, 2025, Yipinhong had 20,700 shareholders, an increase of 9.42% from the previous period. The average circulating shares per person decreased by 8.61% to 20,156 shares [2]. - Notable new shareholders include Hong Kong Central Clearing Limited, holding 4.1496 million shares, and several mutual funds entering the top ten circulating shareholders [3]. Market Activity - On November 14, Yipinhong's stock rose by 2.02%, reaching 52.50 yuan per share, with a trading volume of 165 million yuan and a turnover rate of 0.77%. The total market capitalization is 23.714 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1].

Core Viewpoint - Yipinhong Pharmaceutical Group Co., Ltd. is facing multiple challenges, including a lawsuit for intellectual property disputes amounting to 528.6 million yuan and a significant financial loss due to previous regulatory violations in drug procurement [1][4]. Group 1: Lawsuit Details - The lawsuit traces back to a cooperation agreement signed in October 2014 between Yipinhong Pharmaceutical and Huiyou International, establishing a joint venture for the development of a specific drug [2]. - Huiyou International claims that the intellectual property transferred to the joint venture was originally valued at 88 million yuan, leading to a compensation demand of 528 million yuan, which is six times the original valuation [3]. - Yipinhong asserts that it has fulfilled its payment obligations and has engaged a legal team to contest the lawsuit, believing that Huiyou International lacks the right to initiate the claim [3]. Group 2: Financial Performance - Yipinhong reported a net loss of 540 million yuan for the fiscal year 2024, marking its first loss since going public, with a net profit of -289 million yuan after excluding non-recurring items [4]. - The company attributes its financial downturn to various factors, including industry policy changes, market environment shifts, and increased R&D investments totaling approximately 325 million yuan, a 7.77% increase year-on-year [4]. - The company also faced a significant financial impact from healthcare refunds, amounting to 266 million yuan, which exceeded its net profit for 2023 [5]. Group 3: Regulatory Issues - In July 2024, Yipinhong's subsidiary was found to have violated regulations during a national drug procurement process, resulting in the suspension of its procurement qualifications for six months [5]. - The company has been placed on a "violation list" alongside other firms, further complicating its operational landscape [5]. - Despite the ongoing lawsuit, Yipinhong claims that it does not expect the legal proceedings to affect its daily operations and R&D activities [5].

Core Viewpoint - Recently, Huayou International Ltd. has filed a lawsuit against Yipin Hong Pharmaceutical Co., Ltd. regarding intellectual property disputes, claiming ownership of several patents related to a specific injection formulation and seeking substantial damages [2][3]. Group 1: Lawsuit Details - The lawsuit requests confirmation of ownership of multiple patents for "an injection formulation of prostaglandin E1 and its preparation method" and demands the defendants to cease infringement, along with a compensation claim of 528 million yuan and legal fees of 600,000 yuan [2][3]. - The background of the lawsuit traces back to a cooperation agreement signed on October 31, 2014, where Yipin Hong Pharmaceutical and Huayou International established a joint venture, with Yipin holding 52% and Huayou 48% of the shares [3][4]. Group 2: Financial Performance - For the first three quarters of 2025, Yipin Hong reported revenues of 814 million yuan, a year-on-year decline of 34.35%, and a net loss attributable to shareholders of 136 million yuan, compared to a loss of 247 million yuan in the same period last year [6][7]. - In 2024, Yipin Hong's total revenue was 1.45 billion yuan, down 42.07%, with a net loss of 540 million yuan, contrasting with a profit of 185 million yuan in the previous year [6][7]. Group 3: Regulatory Issues - In August 2024, Yipin Hong's subsidiary was disqualified from participating in the centralized procurement of a specific injection due to violations of procurement regulations, which significantly impacted its revenue from that product [6][7]. - The company has taken corrective measures, including returning medical insurance funds and lowering the price of the affected injection, while its participation in centralized procurement was suspended for six months [7]. Group 4: Future Outlook - Yipin Hong has set performance targets for 2025, including a profit growth rate of no less than 32% compared to 2023, the approval of at least one new innovative drug IND, and obtaining no fewer than 10 drug registration approvals [8]. - As of the mid-2025 report, the company has already achieved significant progress, having received 10 drug registration approvals for 9 self-developed projects [9].

Core Viewpoint - Yipinhong Pharmaceutical Group Co., Ltd. is facing a lawsuit from Huiyou International Ltd. regarding intellectual property disputes, with the claimed amount being 528.6 million yuan [2][3] Group 1: Lawsuit Details - The lawsuit was filed in the Guangdong High People's Court, and the case has been accepted but not yet heard [2] - The dispute traces back to a cooperation agreement signed in October 2014, where Yipinhong's subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., and Huiyou International agreed to establish a joint venture, Guangzhou Pinrui Pharmaceutical Technology Co., Ltd. [2] - The joint venture was established with a cash investment of 10 million yuan, with Yipinhong holding 52% and Huiyou holding 48% [2] Group 2: Claims and Counterclaims - Huiyou International claims that the original valuation of the intellectual property injected into the joint venture was 88 million yuan, leading to a compensation request of 528 million yuan, which is six times the original valuation [3] - The lawsuit requests the defendants to cease infringement on specific patents and to transfer ownership of another patent to Huiyou International [3] Group 3: Company Response - Yipinhong asserts that it has complied with the agreement by paying 15 million yuan in 2015-2016 and denies any breach of contract [4] - The company has engaged a legal team to analyze the lawsuit and believes that the claims made by Huiyou International should be dismissed [4] - Yipinhong emphasizes that the lawsuit will not impact its daily operations or research and development [4] Group 4: Financial Performance - For the first three quarters of 2025, Yipinhong reported revenue of 814 million yuan, a year-on-year decrease of 34.35%, and a net profit of 136 million yuan, with losses narrowing by 44.80% year-on-year [5] - As of the announcement date, Yipinhong and its subsidiaries have other undisclosed litigation matters totaling 5.6312 million yuan, with no claims as a plaintiff [5]